october 4 – 7, 2012 - retina society
TRANSCRIPT
attendee registration packet
OctOber 4 – 7, 2012M a n d a r i n O r i e n ta l
DCDC ★
WashingtonWashington
2
This 45Th AnnuAl scienTific session of The ReTina SocieTy being held at the MandaRin oRienTal in WaShingTon, dc, ocTobeR 4 – 7, 2012, will surely be an unforgettable meeting in our nation’s capital, just weeks before our national elections. We had a record number of abstract submissions, and expect the oral and poster presentations to be exceptional. Washington D.c. is always welcoming to visitors, and our planned social events should be great fun.
Attached you will find:Page 1. Meeting Registration form Page 3. hotel Reservation information Page 5. Program-in-Brief Page 7. social Program (please bring home to spouse or guest)Page 15. Preliminary Program
nonMeMbeR gUeSTS — Members are welcome to invite one nonmember, physician guest, as well as sponsor a physician-in-training, to attend our meeting provided you too are attending the meeting. Please contact Judy cerone Keenan ([email protected]; 617.227.8767) if you wish them to receive this registration material.
online RegiSTRaTion: You will need to log in to the member area to register. nonmember guests will be asked to create a profile, then proceed to registration.
Below is a brief description of our social events. Please see more detailed information on pages 7 – 9 and indicate which events you will attend on the registration form. We highly recommend that you register online and pay by credit card at www.retinasociety.org, however you may also send in the registration form with a check in u.s. DollARs only.
WelcoMing RecePTion — Thursday evening. following the annual interesting Retinal cases and Video conference, join us to meet and greet old and new friends at the Mandarin oriental. We will be entertained by the cAPiTol sTePs, a group of former congressional staffers who will satirize the politics and politicians of the day with music and songs.
libRaRy oF congReSS — friday evening. We are delighted to able to invite you to join us for cocktails and dinner in a spectacular setting at the world’s largest library!
The Program committee
Final banQUeT — saturday evening. our traditional black-tie optional event will be unforgettable with a delectable
dinner and dancing.
Be sure to check our web site from time to time for updated meeting information. have a great summer—see you in
Washington in the fall.
dear ret ina society MeMbers, spouses and guests
1
laST naMe degRee FiRST naMe
addReSS
ciTy STaTe ZiP code coUnTRy (IF NOT USA)
TelePhone FaX e-Mail addReSS (MUST BE INCLUDED)
MeeTing RegiSTRaTion
❏ Member $550 until July 15 $700 July 16 – september 15 $1,000 september 16 – onsite $________________
❏ *nonmember $550 until July 15 $700 July 16 – september 15 $1,000 september 16 – onsite $________________
❏ *fellow-in-training $300 until July 15 $400 July 16 – september 15 $ 500 september 16 – onsite $________________
(Must have accompanying letter from dept. chair.)
* Member Sponsor Name
MuSt be iNcluded— ReGiStRAtiON Will NOt be AccePted WitHOut NAMe OF MeMbeR SPONSOR FOR NONMeMbeRS/FellOWS
❏ spouse/Guest** $350 until July 15 $500 July 16 – september 15 $600 september 16 – onsite $________________
**Full Name of Spouse or Guest
gUeST ToURS (See description page 7.)
❏ friday, hillwood house / lunch / Phillips $100 pp X ________ = $___________
❏ friday, hillwood house /lunch $ 70 pp X ________ = $___________
❏ friday, lunch/Phillips $ 70 pp X ________ = $___________
❏ friday, lunch only $ 35 pp X ________ = $___________
❏ saturday, Private Gardens Tour $ 25 pp X ________ = $___________
Fees include: continental breakfast, breaks, lunch (for physicians), Welcome Receptions, library of congress, and banquet Fees cannot be adjusted for Partial or nonattendance of Social events
❏ cHildReN: Fees for children Attending Social Activities: ❏Under age 6, no Fee ❏6 – 18 years, $300 Please indicate Name(s) and Age(s) of Child(ren)
ToTAl RegisTRATioN Fees eNClosed $________________
Social acTiviTieS RegiSTRaTion MuSt be cOMPleted OR SPAce Will NOt be AvAilAble — iNdicAte “0” iF NOt AtteNdiNG
Thursday evening Welcome Reception (everyone) _____________
Friday Spouses tours: 1) hillwood house / lunch / Phillips ($100) _____________
2) hillwood / lunch only ($70) _____________
3) lunch / Phillips ($70) _____________ 4) lunch only ($35) _____________
Friday evening library of congress (everyone) _____________ Saturday Spouses tour Private gardens of georgetown ($25) _____________
Saturday evening banquet (everyone) _____________
Special dietary Requirements: Please indicate: ❏vegetarian ❏Kosher ❏Other _________________
45th Annual scientific Meeting Mandarin oriental Washington, Dc october 4 – 7, 2012registration ForM
payMent by credit card (Visa, Mastercard, aMeX) May be Made onLine onLy at WWW.retinasociety.orgPLEASE TYPE OR PRINT CLEARLY
cancellaTion and ReFUnd Policy cancellations or requests for refunds must be made in writing. those received on or before to august 1 will be refundable less a $50 surcharge; cancellations received after august 1 are nonrefundable.
Number Attending
Mandarin orientaL
2Exterior Mandarin Oriental, Empress Lounge
Mandarin Oriental — MeetinG HOtel
HoteL reserVations
Water Premiere Suite and Lobby
Mandarin Oriental 1330 Maryland Avenue SW, Washington, DC 20024 www.mandarinoriental.com
Call 202-787-6140 or 1-800-526-6566, ask for Retina Society block.
Click to go directly to hotel website: Mandarin Oriental Registration Page
If web page does not automtically load, copy URL and paste in browser window: https://resweb.passkey.com/Resweb.do?mode=welcome_ei_new&eventID=8121052
Cut-off date — September 13
Feel free to contact Judy Cerone Keenan at 617.227.8767 or [email protected]
if you have any difficulties.
The Mandarin OrienTal
boasts grand elegance within
walking distance of capitol Hill, and
the museums of the smithsonian
institution. ranked by institutional
investor magazine as one of the top
100 hotels in the world.
3
sMitHsonian inst itute
4
tHUrSdaY, OCtOBer 4
12:00 Noon Exhibit set-up — Oriental BallrOOm
12:00 – 3:00 pm Executive Committee Meeting — COrCOran rOOm
4:00 – 7:00 pm Meeting Registration — Pre-FunCtiOn, Grand BallrOOm
5:00 – 7:00 pm Interesting Retinal Case Presentations/Videos – Grand BallrOOm
7:00 – 10:00 pm Welcoming Reception — Capitol Steps — garden terrace/grand ballroom
FridaY, OCtOBer 5
7:00 am Meeting Registration — Pre-FunCtiOn
Continental Breakfast — Oriental BallrOOm
7:30 – 11:00 am Spouses/Guests Hospitality Suite — Garden I & Terrace
8:00 am – 12:14 pm Scientific Session — Grand BallrOOm
9:30 am – 4:30 pm SPOUSES TOURS/LUNCH — See options page 7 – 9
12:14 – 1:14 pm Scientific Session Attendees Lunch
1:14 – 2:14 pm Poster Session/Desserts
2:14 – 4:59 pm Scientific Session — Grand BallrOOm
7:00 – 10:00 pm library of Congress — buses depart 6:45 pm
SatUrdaY, OCtOBer 6
7:00 am Registration/Continental Breakfast/Exhibits
7:30 – 11:00 am Spouses Hospitality Suite — Garden i & terraCe
8:00 – 11:30 am Scientific Session — Grand BallrOOm
9:30 am – 1:00 pm SPOUSES TOUR — Georgetown Private Gardens
11:30 am – 12:00 pm Annual Business Meeting — Grand BallrOOm
12:00 – 1:00 pm Scientific Session Attendees Lunch
1:00 – 5:15 pm Scientific Session — Grand BallrOOm
7:00 – 11:00 pm Reception/Banquet — grand ballroom
SUndaY,OCtOBer 7
7:30 am Continental Breakfast/Exhibits — Oriental BallrOOm
8:15 am – 12:00 pm Scientific Session — Grand BallrOOm
Adjourn
*final program will be sent when available.
preLiMinary prograM- in -brieF
The Retina society 45th Annual scientific Meeting Washington, Dc october 4 – 7, 2012
5
L ibrary oF congress
6
HOspitality suite
AccompAnying persons on Friday and saturday a Hospitality suite in the garden i and Foyer on the first floor will be open from 7:30 – 11:00 am where you may meet and visit or just enjoy coffee, tea, and continental breakfast. on sunday, spouses and guests are welcome to continental breakfast in the oriental ballroom.
THUrsDAy, ocToBer 4
7:00 – 10:00 pm
WelcOMe receptiOn gaRden TeRRace
capitOl steps gRand ballRooM
Join us to say hello to old friends and new at the garden terrace and enjoy tempting cuisine and refreshments. then prepare to laugh yourself silly for 45 minutes with the capitol steps, ‘a troupe of congressional staffers-turned-comedians who travel the country satirizing the very people and places that once employed them.’ their motto, “we put the mock in democracy,“ will be evident! and with just five weeks to election, this should be most entertaining.
FriDAy, ocToBer 5
spoUses ToUrsWe are happy to offer four choices today to our accompanying persons. depending on your inclination, you may either attend:1) Full day: Hillwood House and gardens tour and Lunch followed by phillips collection tour2) Half-day, morning: Hillwood House and gardens and lunch and return to hotel3) Half-day, afternoon: Lunch and phillips collection tour4) Or lunch only
9:30 am – 1:30 pm
HillWOOd MuseuM and Gardens
WitH luncH
Marjorie Merriweather post (1887-1973), heir to the post cereal fortune, was the founder of Hillwood Museum and gardens — her former twenty-five acre estate in Washington, dc. known as one of america’s first businesswoman, she was a distinguished art collector, noted philanthropist, and socialite. guests will tour Mrs. post’s manicured gardens which were
7
Mandarin Oriental garden view, Garden Room, Capitol Steps,
Hillwood Museum and Gardens
88
sociaL prograM
refurbished by perry Wheeler, noted horticulturist who helped design and establish the White House rose gardens, and visit the georgian mansion. built in 1926, this opulent 40 room mansion houses an extensive collection of French and russian fine art and furnishings. Hillwood’s collection of russian icons, gold and silver pieces, porcelain and Faberge eggs have been called the most representative outside of russia.
12:15 – 1:45 pm
luncH
Following the Hillwood Museum and garden tour, guests will enjoy lunch at a local restaurant and be joined by those who may either have lunch only, or have lunch followed by the phillips collection tour.
1:45 pm
cOacHes return
guests may opt to go back to the Mandarin oriental or continue to the phillips collection.
2:00 – 4:30 pm
pHillips cOllectiOn tOur
opened in 1921, the phillips collection is america’s first museum of modern art. Featuring a renowned permanent collection of nearly 2,500 works by american and european impressionists and modern artist, the phillips is internationally recognized for both its incomparable art and its intimate atmosphere. Housed in founder duncan phillips’ 1897 georgian revival home, the phillips collection is widely regarded as one of the world’s finest small museums.
Hillwood Museum Pavillion Room, Duncan Phillips’ Georgian Revival Home, Phillips’ Collection boasts Luncheon of the Boating Party by French Impressionist Pierre-Auguste Renoir among it’s world-renown acquisitions.
9
sociaL prograM
7:00 – 10:00 pm
tHe library Of cOnGress
the Library of congress, the largest library in the world and america’s oldest federal cultural institution, was founded in 1800 to serve the needs of congress. the Library has grown into an unparalleled treasure house of the world’s knowledge and america’s creativity. our reception will be held in the thomas Jefferson building beginning in the great Hall. built in the 1890’s the great Hall is a two-story room decorated in the italian renaissance style with beautiful murals, mosaics, and vaulted marble ceilings. a jazz trio will provide a warm atmosphere as you mingle, enjoy cocktails and passed hors d’oeuvres. dinner buffets will then open and you may sit and enjoy delectable buffet options, and continue exploring the grand space as you wish. docents will be available for information as you meander through two exhibits which will be open for us. not to be missed.
sATUrDAy, ocToBer 6
9:30 am – 1:00 pm
private Gardens tOur
guests will tour three private gardens with spacious lawns, majestic trees and intimate outside rooms. the gardens are owned by members of the georgetown garden club which is a member of the garden club of america. one of their members will guide us.
7:00 – 11:00 pm
banquet – black tie OptiOnal
you must join us at our annual elegant banquet in the grand ballroom of the Mandarin oriental. cocktails and a delectable dinner followed by dancing to one of Washington’s best known orchestras will cap our annual Meeting social events.
Entry Hall Library of Congress, private garden, Mandarin Orient Ballroom
9
L incoLn MeMoriaL
10
11
(at time of printing)
GOld patrOnALCON
patrOn
REGENERON
benefactOrs
AKORN
ARCTIC-DX
CARL ZEISS MEDITEC
HEIDELBERG ENGINEERING
INSIGHT INSTRUMENTS
OPTOS
OPTOVUE
PODIS-GMS
SANTEN
SYNERGETICS
THROMBOGENICS
VISION CARE OPHTHALMIC TECHNOLOGIES
publisHers rOW
RETINA TODAY
RETINAL PHYSICIAN
speciaL tHanks to our eXHib itors
12
u.s. a ir Force MonuMent
13
DiscLosUre:
all speakers have been asked to disclose any significant relationships they may have with commercial companies. the presence or absence of relationships as well as off-label discussion of projects will be disclosed at the time of the meeting.
TArgeT AUDience:
Vitreoretinal ophthalmologists who are members and guests of members of the retina society, as well as fellows-in-training.
goALs AnD oBJecTiVes oF meeTing:
this annual meeting is intended to increase the physician’s knowledge, skills and performance to provide services for patients. topics for discussion will include but are not limited to age-related macular degeneration, diabetic retinopathy, tumors, infections, surgery for retinal detachment and macular disease, anti-VegF agents. at the interesting retinal cases session and Video conference, physicians will be able to participate in discussion and reach a conclusion on treatment of various interesting vitreoretinal cases presented by participants. the attendee’s basic knowledge and treatment skills will be enhanced by the information presented and subsequent discussions.
Upon compLeTion oF THis progrAm, pArTicipAnTs sHoULD Be ABLe To
1. determine when VegF inhibitors can be useful in the management of diabetic macular edema, and the appropriate timing of treatment so as to improve long term visual outcome, and decrease treatment related risk.
2. identify the advantages and disadvantages of various treatment approaches to repair retinal detachment.
3. explain how to incorporate the results of newer imaging techniques such as high resolution oct in the management and diagnosis of a variety of macular diseases including macular degeneration.
4. recognize how choice of drug and dose of drug affects treatment outcome in wet age-related macular degeneration.
5. review newer techniques in the management of intraocular tumors and other diseases.
accreditat ion
WHite House
14
15
preLiMinary prograM — 2012
7:00 am RegiSTRaTion/conTinenTal bReakFaST/eXhibiTS
7:55 WelcOMe: Charles C. Barr, MD, President
diabetes and retinal vascular disease presiding Officer: Julia A. Haller, MD
MOderaTOr: Michael Singer, MD
8:00 am Long term efficacy and safety of ranibizumab in diabetic Macular edema (dMe): 36-month results from rise and ride, two phase iii clinical trials David Boyer, MD
8:06 retinal anatomy, baseline characteristics and Visual acuity: patterns of response to ranibizumab therapy in patients with diabetic Macular edema (dMe) Quan Nguyen, MD, MSc
8:12 Questions
8:18 three-year Follow-up of a randomized trial evaluation ranibizumab plus prompt versus defferred Laser for diabetic Macular edema Lloyd Paul Aiello, MD, PhDQuestions
8:27 Macular edema Following cataract surgery in diabetic eyes without central-involved diabetic Macular edema (dMe)Stephen Kim, MDQuestions
8:36 Fellow eye effect of unilateral intravitreal bevacizumab injection for diabetic Macular edema (dMe) Itay Chowers, MDQuestions
8:45 intravitreal bevacizumab for recurrent Vitreous Hemorrhage after Vitrectomy for diabetic retinopathy Mathew MacCumber, MD, PhDQuestions
8:54 predicting development of proliferative diabetic retinopathyThomas Gardner, MD, MSQuestions
9:03 retinal Hemodynamics in insulin-treated diabetic animals and non-treated diabetic animals in early stages of diabetic retinopathyJennifer Kang-Mieler, PhDQuestions
9:12 prevalence of Visual impairment from diabetic Macular edema and relationship to eye care from the 2005-2008 national Health and nutrition examination survey (nHanes) Neil Bressler, MDQuestions
FriDAy, ocToBer 5
fr
ida
Y, O
cT
OB
er
5
16
preLiMinary prograM — 2012
9:21 results of the phase 3 copernicus study: intravitreal afibercepts injection in central retinal Vein occlusion Julia A. Haller, MDQuestions
9:30 baseline characteristics and response to treatment of participants with HrVo compared to participants with brVo and participants in the score studyIngrid Scott, MD, MPHQuestions
9:39 effect of area of peripheral retinal non-perfusion in treatment response in branch and central retinal Vein occlusion Michael Singer, MDQuestions
9:48 pre-eclampsia and retinopathy of prematurity Julia Shulman, MDQuestions
9:57 angiographic phenotypes of Wnt-related Vitreoretinopathies Kimberly Drenser, MD, PhDQuestions
10:06 ReFReShMenT bReak/eXhibiTS
inflaMMatOry disease and practice ManaGeMent presiding Officer: Dennis Han, MD MOderaTOr: Raymond Iezzi, MD
10:36 intravitreous dexamethsone implants for the treatment of retinitis pigmentosa-associated cystoid Macular edema Raymond Iezzi, MD, MSQuestions
10:45 cystoid Macular edema associated with Fingolimod (gilenya) 0.5 mg use for Multiple sclerosis Seenu Hariprasad, MDQuestions
10:54 Multicenter study of infliximb for refractory uveoretinitis in behcet’s diseaseAnnabelle Okada, MDQuestions
11:03 particle-induced endophthalmitis: a possible new Mechanism of sterile endophthalmitis after intravitreous triamcinolone Taiji Sakamoto, MD, PhDQuestions
11:12 bacterial cultures and sensitivities before and after intravitreal injection Charles C. Barr, MDQuestions
11:21 clinical and economic impact of the implementation of electronic Medical records Rishi Singh, MDQuestions
fr
ida
Y, O
cT
OB
er
5
17
preLiMinary prograM — 2012
11:30 Lean processes in action: From toyota to ophthalmic practice Dennis Han, MDQuestions
11:39 J. donald M. gaSS lecTURe Lessons Learned from an outbreak of streptococcus endophthalmitis after intravitreal
injection of bevacizumabHarry W. Flynn, Jr., MD
12:04 pm FelloWShiP ReSeaRch aWaRd Maturation of the Human Fovea: correlation of spectral domain optical coherence
tomography Findings with Histology Lejla Vajzovic, MDQuestions
12:14 – 1:14 lUnch
1:14 - 2:14 PoSTeR vieWing/deSSeRT
iMaGinG presiding Officer: Cynthia Toth, MD MOderaTOr: R. V. Paul Chan, MD
2:14 ultra-widefield Fluorescein angiography characteristics of recalcitrant diabetic Macular edema Ravi Patel, MDQuestions
2:23 assessment of time-domain and spectral-domain ocular coherence tomography in the Management of diabetic Macular edema with anti-VegF therapy Susan Bressler, MDQuestions
2:32 a comparison of retinal thickness and Volume reproducibility from Zeiss stratus time domain and Heidelberg spectralis spectral domain optical coherence tomography imaging of eyes with diabetic Macular edema Jennifer Sun, MDQuestions
2:41 comparative analysis of the retinal Microvasculature Visualized with Fluorescein angiography and the retinal Function imager Sunir Garg, MD, FACSQuestions
2:50 non-invasive Multi-spectral Fundus imaging is a useful tool for structural and Functional evaluation of the choroidal Vasculature Brian Leonard, MDQuestions
2:59 adaptive optics imaging of eyes with epiretinal Membranes before and after surgeryMario Stirpe, MDQuestions
fr
ida
Y, O
cT
OB
er
5
18
3:08 Handheld and Microscope-integrated spectral domain optical coherence tomography in Human and experimental Vitreoretinal surgeryCynthia Toth, MDQuestions
3:17 prospective analysis of intraoperative and trans-tamponade optical coherence tomography for Vitreoretinal surgery: pioneer study 6-month Vitreoretinal resultsJustis Ehlers, MDQuestions
3:26 ReFReShMenT bReak/eXhibiTS
Macular disease presiding Officer: Mark W. Johnson, MD MOderaTOr: Audina Berrocal, MD
3:56 acute Macular neuroretinopathy: insights from Multimodal imaging and Long-term Follow-up Amani Fawzi, MDQuestions
4:05 Multilayered pigment epithelial detachment (ped): a new spectral domain optical coherence tomography (sd-oct) Finding in 15 eyes with type 1 choroidal neovascularization Ehsan Raimy, MDQuestions
4:14 optical coherence tomography imaging of subretinal pigment epithelium Lipid (the “onion sign”)K. Bailey Freund, MDQuestions
4:23 non-hereditary Foveomacular retinitis Michael Ober, MDQuestions
4:32 Fundus autofluorescence Quantification of dry age-related Macular degeneration (aMd) using a pixel Mapping technique Thiran Jayasundera, MDQuestions
4:41 choroidal atrophy in patients with non-neovascular age-related Macular degenerationSumit Sharma, MDQuestions
4:50 initial experience with oral rifampin for treatment of central serous chorioretinopathy (csc) Zac Ravage, MDQuestions
4:59 adJoURn
preLiMinary prograM — 2012
fr
ida
Y, O
cT
OB
er
5
19
sATUrDAy, ocToBer 6
7:00 am RegiSTRaTion/conTinenTal bReakFaST/eXhibiTS
vitreOretinal surGery i presiding Officer: Reginald Sanders, MD MOderaTOr: John Christoforidis, MD
8:00 am Micron: an actively stabilized Microsurgical instrumentLouis Lobes, MDQuestions
8:09 sutureless small gauge Vitrectomy for relief of symptomatic Vitreous Floaters John Mason, III, MDQuestions
8:18 Floaterectomy: effects on patients Quality of Life Frank Koch, MDQuestions
8:27 analysis of Long-term outcomes for combined pars plana Vitrectomy (ppV) and glaucoma tube shunt surgery in eyes with advanced glaucoma Daniel Miller, MD, PhDQuestions
8:36 Macular Hole surgery results with Long-acting gas tamponade and internal Limiting Membrane removalJohn Thompson, MDQuestions
8:45 serous subfoveal retinal detachment following idiopathic Macular Hole surgery Kapil Kapoor, MDQuestions
8:54 brilliant blue g (bbg) versus indocyanine green (icg) for staining internal Limiting Membrane in Macular pucker surgery Christine Gonzales, MDQuestions
9:03 ultrahigh-speed Vitrectomy is a real advantage? Stanislao Rizzo, MDQuestions
9:12 27 gauge pars-plana Vitrectomy: the cincinnati experienceMario DelCid, MDQuestions
9:21 reFReShMenT bReak/eXhibiTS
sa
TU
rd
aY
, O
cT
OB
er
6
preLiMinary prograM — 2012
20
vitreOretinal surGery ii presiding Officer: Bernard Doft, MD MOderaTOr: Thomas M. Aaberg, Jr., MD
9:51 epiretinal Membrane and cystoid Macular edema following uncomplicated primary retinal detachment repair with small gauge pars plana Vitrectomy Gayatri Reilly, MDQuestions
10:00 incidence of retinal detachment following cataract surgery with presbyopia-correcting intraocular Lenses Michael Lai, MD, PhDQuestions
10:09 cost-effectiveness analysis of scleral buckle versus Vitrectomy for rhegmatogenous retinal detachmentJay Stewart, MDQuestions
10:18 a simple technique for direct silicone Heavy Liquid exchange in small gauge pars plana Vitrectomy Bernard Doft, MDQuestions
10:27 ocriplasmin single intravitreal injection for the resolution of symptomatic Vitreomacular adhesion (VMa) including Macular Hole: results of the MiVi-trust phase iii program Michael J. Trese, MDQuestions
10:36 the impact of Vitreomacular adhesion resolution on Visual acuity: an analysis of the phase iii MiVi-trust program Tarek Hassan, MDQuestions
10:45 optical coherence tomography anatomic Features that affect outcomes for Vitreomacular adhesion, Macular Hole, and Visual acuity in the phase iii clinical program of ocriplasmin Vitreolysis Francisco Folgar, MDQuestions
10:54 ReTina ReSeaRch aWaRd oF MeRiT – chaRleS l. SchePenS lecTURe retinal pigment epithelial cell Loss assessed by Fundus autofluorescence in patients
with neovascular age-related Macular degenerationRichard Spaide, MD
11:19 RayMond R. MaRgheRio aWaRd PReSenTaTion High throughput Mass spectrometry-based Mutation profiling of primary uveal Melanoma
Anthony Daniels, MDQuestions
11:30 annUal bUSineSS MeeTing
12:00 – 1:00 pm lUnch
preLiMinary prograM — 2012
sa
TU
rd
aY
, O
cT
OB
er
6
21
aGe-related Macular deGeneratiOn ipresiding Officer: Allen Ho, MDMOderaTOr: Jeffrey S. Heier, MD
1:00 reduced retinal blood Flow Velocity in patients with age-relatedMacular degenerationAdiel Barak, MDQuestions
1:09 the Long term safety profile of intravitreal anti-VegF: an inVivo study of inner retina and corneal nerve plexus Edoardo Midena, MD, PhDQuestions
1:18 acquired Vitelliform Lesion associated with Large drusenLuiz Lima, MDQuestions
1:27 non-genetic and genetic risk Factors: update on predictive Models for age-related Macular degeneration Johanna Seddon, MD, ScMQuestions
1:36 genetic analysis of concordant versus discordant age-related Macular degenerationStephen Schwartz, MDQuestions
1:45 stem cell based therapy for atrophic age-related Macular degenerationAllen Ho, MDQuestions
1:54 systemic complement inhibition with eculizumab for the treatment of non-exudative age-related Macular degeneration: the coMpLete study Philip Rosenfeld, MDQuestions
2:03 expression of endostatin and angiostatin after subretinal injection of retinostat; preliminary results from the gene transfer of endostatin/angiostatin for Macular degeneration (geM) trial Peter Campochiaro, MDQuestions
2:12 Multicenter phase 1 clinical trial targeting tissue Factor for the treatment of neovascular age-related Macular degeneration John Wells, III, MDQuestions
2:21 sustained delivery of a VegF antagonist by encapsulated cell intraocular implant for the treatment of Wet age-related Macular degeneration Glenn Jaffe, MDQuestions
sa
TU
rd
aY
, O
cT
OB
er
6
preLiMinary prograM — 2012
22
2:30 Visual and anatomic outcomes of anti-VegF therapy in exudative age-related Macular degeneration and Vitreomacular interface diseaseSophie Bakri, MDQuestions
2:39 the use of at-home electronic Visual testing to enhance optimization of anti-VegF treatment regimens and patient-physician communication Mark S. Blumenkranz, MDQuestions
2:48 ReFReShMenT bReak/eXhibiTS
tuMOrs presiding Officer: Timothy Murray, MDMOderaTOr: Ivana Kim, MD
3:18 Vaso-occlusive choroidal pseudotumors: a new syndrome Leonidas Zografos, MDQuestions
3:27 new observations on retinal Vasoproliferative tumors Jerry Shields, MDQuestions
3:36 enhanced depth imaging optical coherence tomography of small choroidal Melanoma. comparative analysis to choroidal nevusCarol Shields, MDQuestions
3:45 risk of radiation retinopathy in patients with orbital and ocular LymphomaMegha Kaushik, MDQuestions
3:54 clinical response to intravitreal High dose (2.0) ranibizumab for radiation MaculopathyPaul Finger, MD, FACSQuestions
4:03 treatment of radiation-associated Maculopathy with intravitreal bevacizumab versus alternating bevacizumab with triamcinoloneWilliam Mieler, MDQuestions
4:12 intravitreal bevacizumab coupled with 125-iodine brachytherapy improves anatomic and Visual outcomes in the treatment of posterior uveal Melanoma Timothy Murray, MD, MBAQuestions
4:21 Long-term risk of Melanoma-related Mortality in patients with uveal Melanoma treated with proton therapy Evangelos Gragoudas, MDQuestions
preL iMinary prograM — 2012
sa
TU
rd
aY
, O
cT
OB
er
6
23
4:30 outcomes of prescription dose alterations for iodine-125 plaque brachytherapy for posterior uveal Melanoma (uM): 7600cgy versus <7600cgyPrithvi Mruthyunjaya, MDQuestions
4:39 changing indications for Fnab of intraocular tumors over three decadesJames Augsburger, MDQuestions
4:48 risk of Metastasis associated with Fine needle biopsy in uveal MelanomaJ. William Harbour, MDQuestions
4:57 bridge therapy for retinoblastoma in the First three Months of Life David Abramson, MDQuestions
5:06 germline bap1 inactivation is associated with Metastatic ocular Melanoma and cutaneous-ocular Melanoma FamiliesIvana Kim, MDQuestions
5:15 adJoURn
sUnDAy, ocToBer 7
7:30 am RegiSTRaTion/conTinenTal bReakFaST/eXhibiTS
basic sciencepresiding Officer: Mark S. Blumenkranz, MDMOderaTOr: David Zacks, MD
8:15 am subretinal raaV.sFl-1 phase i/ii trial for Wet age-related Macular degenerationIan Constable, FRANCZOQuestions
8:24 serum Huntingtin Level is associated with the presence and the severity of diabetic retinopathy Tongalp Tezel, MDQuestions
8:33 inhibition of choroidal neovascularization by exosomes from retinal glial cells Henry Kaplan, MDQuestions
8:42 circadian-rhythm and dark-light control of autophagy in photoreceptor and retinal pigment epithelial cellsDavid Zacks, MD, PhDQuestions
sU
nd
aY
, O
cT
OB
er
7
preLiMinary prograM — 2012
24
8:51 strategies to generate safe retinal pigment epithelial cells for retinal rehabilitationTravis Meredith, MDQuestions
9:00 a novel surgical Method and support device for translocating autologous tissue grafts to the sub-area centralis: in vivo porcine Model Timothy Olsen, MDQuestions
9:09 integrin peptide therapy: the First Human diabetic Macular edema experience in a phase i trialBaruch Kuppermann, MD, PhDQuestions
9:18 infection of Human retinal pigment epithelium with adenovirus causes cell death: a Model for geographic atrophy? Lucian Del Priore, MD, PhDQuestions
9:27 Macular capillary recruitment in relative Hypoxia as a Homeostatic adaptation with pathologic implicationsJoseph Maguire, MDQuestions
9:36 oxidized phospholipids as proinflammatory and proangiogenic Mediators in retinal diseaseUrsula Schmidt-Erfurth, MDQuestions
9:45 increased Vision with QLt091001 in blindness due to Mutations in retinal pigment epithelium-specific protein 65kda (rpe65) or Lecithin retinol acyltransferace (LratHenrik Scholl, MD, MAQuestions
9:54 ReFReShMenT bReak/eXhibiTS
aGe-related Macular deGeneratiOn iipresiding Officer: Henry Kaplan, MDMOderaTOr: Anne Fung, MD
10:24 a review of the indications for and subsequent Visual, anatomic and safety results after switching from one anti-VegF therapy agent to another in age-related Macular degenerationSundeep Dev, MDQuestions
10:33 predictors and potential Mechanisms of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth Factor therapyQuan Hoang, MDQuestions
preL iMinary prograM — 2012
sU
nd
aY
, O
cT
OB
er
7
25
10:42 submacular Hemorrhage in patients with neovascular age-related Macular degeneration (nvaMd) receiving anti-VegF therapyMichelle Carle, MDQuestions
10:51 Vascularized pigment epithelial detachment treated with 0.5 mg versus 2.0 mg ranibizumab: analysis of results based on Lesion subtype and anatomical outcomeDavid Sarraf, MDQuestions
11:00 2mg ranibizumab for Fibrovascular pigment epithelial detachment refractory to standard dosing: the Hiped study Anne Fung, MDQuestions
11:09 intravitreal aflibercept injection versus ranibizumab for neovascular age-related Macular degeneration: 96 Weeks results from the VieW 1 and VieW 2 studies Jeffrey S. Heier, MDQuestions
11:18 intrepid: a randomized, double-masked, clinical trial of stereotactic radiotherapy for neovascular age-related Macular degenerationTimothy Jackson, PhD, FRCOphthQuestions
11:27 association of baseline Lesion size with best-corrected Visual acuity (bcVa) at Month 12 in ranibizumab studiesAnthony Adamis, MDQuestions
11:36 the Harbor study: effect of every 4 Weeks versus prn dosing with ranibizumab (2.0 mg vs. 0.5 mg) on patient-reported Visual Function in subfoveal neovascular age-related Macular degenerationIvan Suner, MD
11:42 early optical coherence tomography (oct) responses at day 7 and Month 1 post ranibizumab that predict Visual acuity outcomes and injection Frequency at Month 12 in the Harbor studySriniVas Sadda, MD
11:48 Harbor study: use of optical coherence tomography to define dry status and its association with Visual acuity outcomes after ranibizumab treatmentDavid Brown, MD
11:54 Questions
12:00 pm adJoURn
sU
nd
aY
, O
cT
OB
er
7
preLiMinary prograM — 2012
26
WasHington MonuMent at sunset
27
poster prograM
diabetes and retinal vascular disease
pOsTer 1 comparative study of initial ozurdex versus avastin in the treatment of Macular edema following central retinal Vein occlusion (crVo)Vincent Deramo, MD
pOsTer 2 intravitreal ranibizumab for Macular edema secondary to retinal Vein occlusionHyung-Woo Kwak, MD
pOsTer 3 associated treatment with Laser Macular photocoagulation and intravitreal bevacizumab for Macular edema secondary to central retinal Vein occlusion (crVo)Arnaldo Bordon, MD, PhD
pOsTer 4 bevacizumab for Macular edema secondary to crVo in Wyburn Mason syndromeDimitra Skondra, MD
pOsTer 5 idiopathic isolated periarteritisAnita Agarwal, MD
pOsTer 6 posterior segment Manifestations of sleep apneaRon Adelman, MD
pOsTer 7 photobiomodulation as a novel treatment in diabetic retinopathyJohnny Tang, MD
pOsTer 8 c-reaLity (canadian burden of diabetic Macular edema observational study)John Gonder, MD
pOsTer 9 using google tools and survey to assess diabetic retinopathy in pregnancyGloria Wu, MD
pOsTer 10 knowledge, attitude and practice in self-reported diabetics in tertiary eye care centers in eastern india. the LVpei eye and diabetic study (Lead) report #2Taraprasad Das, MD
inflaMMatOry disease
pOsTer 11 Histopathologic correlation of enucleated globes following aspergillus endophthalmitis after uncomplicated cataract surgerySander Dubovy, MD
pOsTer 12 pars plana Vitrectomy in the Management of patients diagnosed with endophthalmitis following intravitreal anti-VegF injectionKhurram Chaudhary, MD
pOsTer 13 transvitreal Fibrinoid pseudo-endophthalmitis after diabetic VitrectomyAlan Ruby, MD
pOsTer 14 peripheral retinal neovascularization in recurrent toxoplasmic retinochoroiditisAlvaro Rodriguez, MD
28
poster prograM
iMaGinG
pOsTer 15 characterization of Vitreoretinal interface disorders using oct in the interventional phase 3 trials of ocriplasminFrancis DeCroos
pOsTer 16 Fundus autofluorescence Findings of choroidal outcomeRobert Sisk, MD
pOsTer 17 ophthalmicedge.org Version 2.0: expansion and analytics of a Free educational WebsiteDavid Kim, MD
pOsTer 18 the orbis cyber-sight retina telementoring experience, 2003-2012Saad Shaikh, MD
surGery
pOsTer 19 posterior Hyaloid detachment and internal Limiting Membrane peeling assisted by 10 natural Vital dyes: experimental studyMichel Farah, MD
pOsTer 20 correlation between the un-aided observation of the iLM and brilliant blue stained iLM following epimacular Membrane peeling: results of the pan american collaborative retina study groupLihteh Wu, MD
pOsTer 21 triamcinolone acetonide (ta) assisted removal of internal Limiting Membrane (iLM)Homayoun Tabandeh, MD, MS
pOsTer 22 25-gauge pars-plana Vitrectomy: an analysis of 2500 consecutive casesPeriklis Brazitikos, MD
pOsTer 23 the VersaVit: a new portable small gauge Vitrectomy unitThomas Aaberg Jr., MD
pOsTer 24 combined endoscopic Vitrectomy with pars plana tube shunt procedureChristopher Riemann, MD
pOsTer 25 symptomatic posterior Vitreous detachment: the predictive Value of the posterior Hyaloid Face and symptomatologyChristiane Falkner-Radler, MD
pOsTer 26 Vitreomacular traction as a consequence of posterior Hyaloidal contraction following transpupillary thermotherapy (ttt)Amir Kashani, MD
pOsTer 27 primary repair of rhegmatogenous retinal detachment by Vitreoretinal Fellows in a county Health systemJean-Pierre Hubschman, MD
pOsTer 28 trans-scleral needle drainage of subretinal Fluid for Vitrectomy repair of retinal detachmentLawrence Chong, MD
pOsTer 29 Video indirect ophthalmoscopy as a clinical teaching toolEdwin Ryan, MD
29
poster prograM
pOsTer 30 intraoperative Visualization of peripheral retina with Wide-angle Viewing systemsFiras Rahhal, MD
pOsTer 31 incidence of steroid-induced ocular Hypertension following Vitreoretinal surgery with difluprednate versus prednisolone acetateHoward Fine, MD
pOsTer 32 sclerotomy closure for retisert implantBrian Berger, MD
pOsTer 33 Late recurrence of Myopic Foveoschisis after successful repair with primary Vitrectomy and MembranectomySung Pyo Park, MD
aGe-related Macular deGeneratiOn
pOsTer 34 drusen in neovascular age-related Maculopathy in korean patientsSeung-Young Yu, MD, PhD
pOsTer 35 retinal Vessel diameters after intravitreal bevacizumab and ranibizumab injectionOsman Cekic, MD, PhD
pOsTer 36 intravitreal clearances of bevacizumab and ranibizumab following Vitrectomy and LensectomyJohn Christoforidis, MD
pOsTer 37 the effect of intravitreal anti-VegF injection on corneal esthesiometryUday Desai, MD
pOsTer 38 novel ophthalmic Microrna biomarkers for diabetic retinopathy and age-related Macular degenerationLawrence Morse, MD, PhD
pOsTer 39 initial early clinical experience with aflibercept for Wet age-related Macular degenerationPhilip Ferrone, MD
pOsTer 40 Mobile Home Vision Monitoring for neovascular Macular degenerationPravin Dugel, MD
tuMOrs
pOsTer 41 dosimetric benefit of a new ophthalmic radiation plaqueArun Singh, MD
pOsTer 42 transvitreal endoresection of refractory retinal capillary Hemoangioblastoma after Ligating the Feeder VesselsGibran Khurshid, MBBS, MD
pOsTer 43 depression of photopic electroretinogram (erg) responses following ocular Manipulation in the Fellow eyes of unilateral retinoblastoma patientsJasmine Francis
30
poster prograM
basic science
pOsTer 44 identification of p2X7 in Human VitreousDeeba Husain, MD
pOsTer 45 injectable sustained release drug delivery platform for anti-VegFs using a reverse thermal gelThomas Friberg, MD
pOsTer 46 identification of diabetic retinopathy genes through a genome-wide association study among Mexican-americansVictor Gonzalez, MD
pOsTer 47 Monocyte chemotactant protein 1 (Mcp-1): a novel therapeutic target in diabetic retinopathyArup Das, MD, PhD
pOsTer 48 thermodynamics of Vitreoretinal surgeryMario Romano, MD, PhD
retinOpatHy Of preMaturity
pOsTer 49 the use of digital imaging in the identification of skip areas after Laser treatment for retinopathy of prematurity and its implication for education and patient careR.V. Paul Chan
pOsTer 50 surgical repair of retinal detachment in Juvenile retinopathy of prematurityFranco Recchia, MD
pOsTer 51 digital Fluorescein angiography guided treatment for pediatric peripheral retinal diseasesAudina Berrocal, MD
TH
E RETINA SOCIETY
1 96 8
The Retina SocietyP.O. Box 6305
Boston, MA 02114617.227.8767
attendee reg istrat ion packet